 Drugbiotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson Johnson JNJ, Novo Nordisk NVO, Merck MRK and AstraZeneca AZN are worth retaining in your portfolio. 